Essential Thrombocythemia – Current Treatment – Detailed, Expanded Analysis (US) Treatment Algorithms: Claims Data Analysis

Essential thrombocythemia (ET) is a rare chronic myeloproliferative disease characterized by the overproduction of platelets. While the etiology of ET is not fully understood, a genetic mutation may be accountable in most cases. With proper treatment, patients with the disease generally have normal life expectancies that are of excellent quality. Depending on the severity of the patient’s diagnosis, different drug classes can be used to target appropriate mechanisms. Anticoagulant therapies, for example, can be used to prevent clotting, while PDE-3 inhibitors such as anagrelide (Takeda’s Agrylin, generics) can be used to reduce the number of platelets.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed ET patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed ET patients?
  • How have therapies such as anagrelide and rivaroxaban (Janssen’s Xarelto) been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of ET patients receive drug therapy after diagnosis and how quickly? What percentage of patients progress to later lines of therapy after diagnosis?
  • What percentage of ET patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key drugs: Anagrelide, aspirin, edoxaban, enoxaparin, hydroxyurea, rivaroxaban, ruxolitinib

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

SOLUTION ENHANCEMENT

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.

Table of contents

  • Essential Thrombocythemia - Current Treatment - Detailed, Expanded Analysis (US) Treatment Algorithms: Claims Data Analysis
    • Treatment Algorithms CDA Essential Thrombocythemia US February 2022
    • Treatment Algorithms CDA Essential Thrombocythemia 2022 Dashboard

launch Related Market Assessment Reports